Search | Clinical Trials Finder

Conditions: Leukemia, Acute Lymphocytic Leukemia
Interventions: Everolimus (RAD001), Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone, Mesna, Methotrexate, Ara-C (Cytarabine), Methylprednisone, G-CSF; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 10 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Relapsed Adult AML, Refractory AML
Interventions: Navitoclax Dose Level 1, Navitoclax Dose Level 0, Navitoclax Dose Level 2, Venetoclax Dose Level -1, Venetoclax Dose Levels 0 to 2, Cladribine, Cytarabine (Cladribine Low Dose Cytarabine Backbone), Cytarabine (CLAG-M Backbone), Mitoxantrone, Granulocyte Colony-Stimulating Factor; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Acute Myeloid Leukemia
Interventions: Idarubicin, Cytarabine, Indoximod Freebase, Indoximod HCL F1, Indoximod HCL F2; Drug
Lead sponsor: NewLink Genetics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Augusta, Georgia • Baltimore, Maryland

Conditions: Hodgkin Disease, Hodgkin Lymphoma
Interventions: Auto stem cell transplant, BEAM, 111In-daclizumab, 90Y-daclizumab; Procedure · Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leukemia
Interventions: Omacetaxine, Cytarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia, in Relapse
Interventions: pembrolizumab,; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 2
States / cities: Baltimore, Maryland • Chapel Hill, North Carolina

Conditions: Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Childhood Nodular Sclerosis Classical Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
Interventions: Bleomycin Sulfate, Cisplatin, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Involved-Field Radiation Therapy, Prednisone, Vincristine Sulfate Liposome; Biological · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 1,734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 153
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 127 more

Conditions: Chronic Myelogenous Leukemia
Interventions: imatinib mesilate, interferon-alpha (INF-a), cytarabine (ARA-C); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2012
U.S. locations: 62
States / cities: Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 50 more

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Quizartinib, Total-Body Irradiation, Venetoclax; Procedure · Drug · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 347
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 265 more

Conditions: Leukemia
Interventions: filgrastim, busulfan, cytarabine, etoposide, methotrexate, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 15 Years to 69 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2009
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Paterson, New Jersey

Conditions: T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Interventions: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Mercaptopurine, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Venetoclax, Vincristine Sulfate; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hematologic Malignancies, AML
Interventions: CP-4055; Drug
Lead sponsor: Clavis Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 5
States / cities: Valhalla, New York • Durham, North Carolina • Cleveland, Ohio + 2 more

Conditions: Hematologic Malignancies
Interventions: L-leucyl-L-leucine Methyl Ester (LLME), Fludarabine, Cytarabine, Cyclophosphamide, Tacrolimus, Mesna, Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF), Hematopoietic stem cell transplantation (HSCT); Drug · Biological · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: rituximab, busulfan, carmustine, cyclophosphamide, cytarabine, etoposide, fludarabine phosphate, melphalan, total body irradiation (TBI), anti-thymocyte globulin IV; Biological · Drug · Radiation
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)
Interventions: CPX-351; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 5
States / cities: Los Angeles, California • Gainesville, Florida • Indianapolis, Indiana + 2 more

Conditions: Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Graft Versus Host Disease, Hodgkin Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Secondary Myelodysplastic Syndrome
Interventions: Busulfan, Cyclophosphamide, Fludarabine Phosphate, Hematopoietic Cell Transplantation, Laboratory Biomarker Analysis, Melphalan Hydrochloride, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Quality-of-Life Assessment, Tacrolimus, Total-Body Irradiation; Drug · Procedure · Other + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 5 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Duarte, California

Conditions: Leukemia
Interventions: Cladribine, Cytarabine, Decitabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Panobinostat; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 5
States / cities: Stanford, California • Boston, Massachusetts • Columbus, Ohio + 2 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: Cladribine, Cytarabine, Decitabine, azacitidine or decitabine, Venetoclax; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Neuroblastoma, Lymphoma, High-risk Tumor
Interventions: CD133+ selected autologous stem cell infusion, IL-2, hu14.18K322A, Busulfan, Melphalan, GM-CSF, Bendamustine, Etoposide, Cytarabine, Carboplatin, Haploidentical natural killer cell infusion, G-CSF, Etoposide phosphate, CliniMACS; Biological · Drug · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Recurrent Pediatric ALL, Relapsed Pediatric ALL, Acute Lymphoblastic Leukemia, Refractory Pediatric ALL
Interventions: ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Cyclophosphamide, 6-thioguanine; Drug
Lead sponsor: Therapeutic Advances in Childhood Leukemia Consortium; Other
Eligibility: Up to 21 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 5
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 2 more

Conditions: Lymphoma
Interventions: Rituximab, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Ifosfamide, Leucovorin, Methotrexate, Thalidomide, Vincristine, Mesna, Filgrastim (G-CSF), Granisetron, Decadron; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Leukemia
Interventions: AEG35156; Drug
Lead sponsor: Aegera Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Los Angeles, California • Denver, Colorado • Chicago, Illinois + 3 more

Conditions: Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)
Interventions: 5hmC Biomarker, Venetoclax, Decitabine 20 mg/m²/day for 5 days, Azacitidine (AZA), Cytarabine (Ara-C), Anthracycline; Diagnostic Test · Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia

Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma

Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies

Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

ABT-751 With Chemotherapy for Relapsed Pediatric ALL

R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker